The results of a first-of its-kind health care provider’s ketamine-treatment plan for Dr. Bronner Magic Soap employees have revealed significant improvement in mental health among participants.
Enthea, which says it is the first and only licensed health insurance benefits provider that covers psychedelics-assisted treatment, shared results of the year-long partnership with Dr. Bronner’s, which makes hemp-based soaps and other products, and whose CEO David Bronner has advocated for and helped fund psychedelics reform efforts across the country.
Enthea announced in a Wednesday press release that approximately seven percent of Dr. Bronner’s employees have taken advantage of this unique ketamine benefit and completed treatment since January 2022. It was the first instance that Enthea allowed a company add ketamine assisted therapy to their employer-sponsored health plan.
The dissociative drug was reported to have improved the symptoms of anxiety and depression by 65 percent by employees who had completed the sessions, which were facilitated by San Diego’s Flow Integrative.
This is incredibly important to us at Dr. Bronner’s and is key to our mission,” span class=”xn-person”>Bronner a href=”https://www.prnewswire.com/news-releases/enthea/reports-clinical results from the first year of psychedelic healthcare benefit for employees of leading California based soap company-301896577.html” rel=”noopener” target=”_blank It is important for us to Dr. Bronner and it is essential to our mission,” Bronner stated.
He said, “I’m proud to partner with Enthea and offer ketamine assisted therapy to our employees.” While not everyone has experienced such profound healing, many members of our team have reported dramatic changes in their lives due to ketamine assisted therapy. We hope that other companies and organisations will also partner with Enthea to offer this benefit to staff.
The FDA has approved ketamine for use as an anesthetic. It is not approved to treat psychiatric disorders at this time, but doctors can administer it off-label just like with any other drug. Esketamine, an FDA-approved nasal syringe that has similar effects, is approved for treatment-resistant depression. It is classified as Schedule III.
Nora Volkow, Director of the National Institute on Drug Abuse in 2021, said that the research on ketamine‘s benefits for treatment-resistant Depression was “eye opening” and that there are more studies on the horizon. She said that “we have funded ongoing research–on ketamine as an opiate treatment, and ketamine to treat pain.”
Bronner, who is also the soap magnate, revealed at a conference last month that he’s backing similar reform endeavors in Massachusetts as well as Arizona. He has provided funding for the New Approach PAC which was instrumental in putting successful psychedelic legalization initiatives on the ballot in Oregon. At a recent conference, the soap magnate revealed that similar reform efforts are being supported in Massachusetts and Arizona.
Enthea said, last year, that it plans to add MDMA and Psilocybin to its toolbox of psychedelics treatments, pending FDA approval.
Nue Life, a wellness provider, and Dr. Bronner’s ketamine partnership have prompted the company to expand their treatment plan. This includes telemedicine as well as at-home care for ketamine.
Juan Pablo Cappello said, “Enthea is working with Nue Life to provide cutting edge mental health solutions no matter where they are.” We are thrilled to be Enthea’s first partner in at-home treatments and to provide cutting-edge methods to capture patient data, so Enthea is able to achieve its mission and demonstrate outcomes.
Biden Admin Has No Record Of Marijuana Letter Cited By DEA Head In Congressional Testimony
Photo courtesy of Wikimedia/Psychonaught.
Bronner’s Workers Who Received Company-Funded Ketamine Therapy Coverage Report ‘Dramatic Improvements’ In Mental Health appeared first on Marijuana Moment. Bronner’s Workers Who Received Company Funded Ketamine Therapy Coverage Report ‘Dramatic Improvements’ In Mental Health first appeared on Marijuana Moment.
